http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Monolayer-covered Aluminum Surfaces Exhibiting Negligible Contact Angle Hysteresis
Atsushi Hozumi,Dalton F. Cheng 한국표면공학회 2010 한국표면공학회 학술발표회 초록집 Vol.2010 No.11
Hydrophobic oxidized aluminum (Al<SUP>Al2O3</SUP>) surfaces exhibiting negligible contact angle hysteresis were prepared by chemical vapor depostion (CVD) of bis((tridecafluoro-1,1,2,2,tetrahydrooctyl)-dimethylsiloxy)methylsilane (F₂?H). XPS and AFM confirmed that our facile CVD method produces monolayers with thicknesses of ~1.2 ㎚ on the Al<SUP>Al2O3</SUP> surfaces without discernible change in surface morphology. After F26H monolayer deposition, hydrophilic Al<SUP>Al2O3</SUP> surface became hydrophobic and exhibited virtually no water contact angle hysteresis (advancing/receding water contact angles (θ<SUB>A</SUB>/θ<SUB>R</SUB>)=110°/109°). Water droplets on these low-hysteresis hydrophobic surfaces moved very easily without “pinning”. They also show excellent anti-collosion properties.
Kumagai, Hozumi,Kusaba, Hitoshi,Okumura, Yuta,Komoda, Masato,Nakano, Michitaka,Tamura, Shingo,Uchida, Mayako,Nagata, Kenichiro,Arita, Shuji,Ariyama, Hiroshi,Takaishi, Shigeo,Akashi, Koichi,Baba, Eishi Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.1
Background: Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination. Materials and Methods: To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy. Results: Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups. Conclusions: Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.